Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme

Elspeth Lamont, R. Andrew Seaton, Merran MacPherson, Lindsay Semple, Emma Bell, A.H. Thomson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The long elimination half-life of teicoplanin facilitates outpatient parenteral antibiotic therapy (OPAT) with thrice-weekly dosing. This study aimed to develop teicoplanin dosage guidelines for OPAT use from routine clinical data. Patients received 15-25 mg/kg/day for 3 days, then 15-25 mg/kg thrice weekly. Trough concentrations were measured weekly and doses adjusted to maintain 20-30 or 10-20 mg/L according to clinical condition. Concentration-time data were analysed using the pharmacokinetic package NONMEM and the final model was used to develop new dosage guidelines. Data from 94 and 36 patients were used for model development and validation, respectively. Patient ages ranged from 15 to 94 years, weights from 43 to 146 kg and estimated CLCR from 9 to 195 mL/min. Teicoplanin concentrations (n = 670) ranged from 6.7 to 66.9 mg/L and a one-compartment model adequately described the data. The typical estimate of CL was 0.542 L/h and changed by 10.6% for every 10 mL/min difference from a CLCR of 66 mL/min. V was 1.62 L/kg. Dosage guidelines based on body weight and CLCR can be expected to lead to a significant improvement in the proportion of concentrations in the range 20-30 mg/L. Alternative doses aimed at lower target concentrations have also been developed. New dosage guidelines have been developed to support thrice-weekly administration of teicoplanin in an OPAT setting.
Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume64
Issue number1
Early online date2 May 2009
DOIs
Publication statusPublished - 2009

Keywords

  • population pharmacokinetics
  • therapeutic drug monitoring
  • extended interval dosing
  • pharmacology

Fingerprint Dive into the research topics of 'Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme'. Together they form a unique fingerprint.

  • Cite this